X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will support Qu Biologics’ preclinical and translational research activities aimed at expanding the portfolio of disease indications, including QBSAU, for the treatment of melanoma.
Lead Product(s): QBSAU
Therapeutic Area: Oncology Product Name: QBSAU
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Natural Sciences and Engineering Council of Canada
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding March 11, 2024
Details:
The net proceeds will be used to fund the Phase 2 clinical trial in late-stage colon cancer evaluating QBECO, an SSI designed to restore innate immune responses in the gastrointestinal tract and related organs, including the liver.
Lead Product(s): QBECO
Therapeutic Area: Oncology Product Name: QBECO
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Accelerating Clinical Trial
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding November 14, 2023
Details:
QBECO-SSI treatment, which is designed to restore normal innate immune function, immune homeostasis, and barrier function in the GI tract, provides a novel potentially transformative alternative to immunosuppressive therapies for patients living with IBD.
Lead Product(s): QBECO-SSI
Therapeutic Area: Gastroenterology Product Name: QBECO-SSI
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Karolinska Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2022
Details:
QBKPN SSI is designed to reprogram the functional competence of immune cells to fix the immune dysregulation that typically develops with aging, providing broad immune protection, not only against COVID-19.
Lead Product(s): QBKPN SSI
Therapeutic Area: Immunology Product Name: QBKPN SSI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Research Council of Canada Industrial Research Assistance Program
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 17, 2022
Details:
QBECO SSI treatment overcomes both cancer-induced and the more profound surgery-induced immune suppression through innate immune training and natural killer cell (NK cell) activation resulting in clearance of cancer cells in the targeted organ.
Lead Product(s): QBECO-SSI
Therapeutic Area: Oncology Product Name: QBECO-SSI
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
QBKPN, a first-in-class innate immune modulator that enhances lung immunity, the treatment can improve the innate immune dysfunction that is present in the context of aging, inflammatory lung diseases, and lung cancer.
Lead Product(s): QBKPN
Therapeutic Area: Infections and Infectious Diseases Product Name: QBKPN
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Health Canada
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
This new equity funding that will allow team and play an essential role in initiating three new Phase 2 randomized placebo-controlled clinical studies of Qbeco. Two of these important trials are in critical indications for which there are no effective treatments.
Lead Product(s): Qbeco
Therapeutic Area: Gastroenterology Product Name: Qbeco SSI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2022
Details:
The purpose of the RESTORE trial was to investigate the effect of QBECO SSI treatment on endoscopic and histologic healing in people living with moderate-to-severe Crohn’s disease.
Lead Product(s): QBECO SSI
Therapeutic Area: Oncology Product Name: QBECO SSI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
This help will expedite the clinical development & deployment of QBKPN for significant unmet need for broad innate immune protection of the lungs, particularly in vulnerable populations such as the elderly & those with co-morbid conditions who lack innate immune resiliency.
Lead Product(s): QBKPN
Therapeutic Area: Infections and Infectious Diseases Product Name: QBKPN
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: NRC IRAP
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 18, 2020
Details:
The study is designed to assess the effect of QBECO SSI treatment on immune function in the tumor and systemically in patients newly diagnosed with colon cancer.
Lead Product(s): QBECO SSI
Therapeutic Area: Oncology Product Name: QBECO SSI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
